Formulary guidance and transparency from P&T to point of care


Reality Check on COPD

Market access for COPD treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 66% of the lives under commercial formularies are covered without utilization management restrictions
  • Class Trends: In July 2020, the FDA approved AstraZeneca’s Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) for the maintenance treatment of patients with chronic obstructive pulmonary disease
  • Key Findings: Once-a-day combination products and monoclonal antibodies have created new opportunities for COPD market growth. The class continues to grow with an influx of pipeline products

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.